Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Combinations in First-Line Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT05909904Phase 2Completed
- Sponsor
- BeiGene
- Start
- Aug 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of tislelizumab, surzebiclimab, alcestobart in head and neck squamous cell carcinoma (HNSCC), sponsored by BeiGene. Started Aug 2023; status: completed.
02
Drugs
tislelizumabsurzebiclimabalcestobart
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05909904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909904.